Shares of Shire PLC (NASDAQ:SHPG) have been assigned an average recommendation of “Buy” from the nineteen research firms that are covering the company, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $206.89.
Several analysts have commented on the company. ValuEngine raised Shire from a “sell” rating to a “hold” rating in a research note on Friday. Evercore ISI downgraded Shire from an “outperform” rating to a “market perform” rating and set a $196.00 price objective for the company. in a research note on Tuesday, September 4th. Sanford C. Bernstein downgraded Shire from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 4th. Royal Bank of Canada set a $188.00 price objective on Shire and gave the company a “buy” rating in a research note on Thursday, July 19th. Finally, BidaskClub upgraded Shire from a “sell” rating to a “hold” rating in a research report on Thursday, September 13th.
SHPG opened at $177.38 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.55 and a debt-to-equity ratio of 0.45. The company has a market cap of $54.22 billion, a price-to-earnings ratio of 11.49, a P/E/G ratio of 1.58 and a beta of 1.22. Shire has a 52 week low of $123.73 and a 52 week high of $181.41.
Shire (NASDAQ:SHPG) last posted its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $3.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.67 by $0.21. The firm had revenue of $3.92 billion during the quarter. Shire had a return on equity of 13.22% and a net margin of 31.06%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the company earned $3.73 earnings per share. equities research analysts expect that Shire will post 15.27 earnings per share for the current fiscal year.
The company also recently declared a dividend, which will be paid on Friday, October 19th. Investors of record on Friday, September 7th will be issued a $0.168 dividend. The ex-dividend date is Thursday, September 6th. Shire’s dividend payout ratio is currently 2.24%.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SHPG. PointState Capital LP grew its holdings in shares of Shire by 4,642.0% in the 2nd quarter. PointState Capital LP now owns 711,296 shares of the biopharmaceutical company’s stock worth $120,067,000 after acquiring an additional 696,296 shares during the period. LMR Partners LLP acquired a new stake in Shire during the 2nd quarter valued at $55,664,000. SG Americas Securities LLC grew its holdings in Shire by 1,634.4% during the 2nd quarter. SG Americas Securities LLC now owns 193,547 shares of the biopharmaceutical company’s stock valued at $32,671,000 after buying an additional 182,388 shares during the last quarter. Prosight Management LP acquired a new stake in Shire during the 1st quarter valued at $21,828,000. Finally, Delek Group Ltd. grew its holdings in Shire by 101.0% during the 1st quarter. Delek Group Ltd. now owns 252,750 shares of the biopharmaceutical company’s stock valued at $37,797,000 after buying an additional 127,000 shares during the last quarter. Institutional investors and hedge funds own 17.84% of the company’s stock.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.